Treatment of tuberculosis in HIV-infected persons in the era of highly active antiretroviral therapy
Gillian Dean(University Hospitals Sussex NHS Foundation Trust), Anton Pozniak, Chris Taylor(King's College Hospital), Annemiek de Ruiter(ViiV Healthcare (Spain)), Graham P. Taylor(NIHR Imperial Biomedical Research Centre), Martin Fisher(Northwell Health), Emma Fox(St George's Hospital), Gail Matthews(UNSW Sydney), Natalie Ives(Cancer Research UK Clinical Trials Unit), Lesley Navaratne(St Thomas' Hospital), Robert F. Miller(University College Hospital), Simon Edwards(Mortimer Market Centre)
Cited by 359
Related Papers
Immunological dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection
|Nature Immunology|2022|987
Tenofovir DF, Emtricitabine, and Efavirenz vs. Zidovudine, Lamivudine, and Efavirenz for HIV
|New England Journal of Medicine|2006|886
Prevalence of Kaposi's sarcoma associated herpesvirus infection measured by antibodies to recombinant capsid protein and latent immunofluorescence antigen
|The Lancet|1996|631